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Summary 
The nefgene product encoded by the mac239 proviral done of simian immunodeficiency virus 
(SIV) markedly enhances viral replication and pathogenesis in vivo. We have used this biologi- 
caUy active nefisolate to examine the phenotype of Nef in retrovirally transduced human T cells 
in culture. SIV Nefis shown to dramatically inhibit cell-surface expression of the CD4 glycopro- 
rein without significantly affecting the total steady-state level of cellular CD4. This downregula- 
tion of the cell-surface CD4 receptor for human immunodeficiency  virus type 1 (HIV-1) infection 
correlated with the acquisition of resistance to superinfection by HIV-1.  However, SIV Nef did 
not affect the level of gene expression directed by the HIV-1 long terminal repeat. It is hypothe- 
sized that downregulation of cell-surface CD4 by Nef facilitates the efficient release of infectious 
progeny virions and, hence, viral spread in vivo. 
T 
he Nef protein of HIV-1 is an NH2-terminally myris- 
toylated protein of '~27 kD that associates with the cy- 
toplasmic membranes of expressing calls (1-3). Nefis expressed 
early in the viral replication cycle from a set of multiply spliced 
mRNA species that also encodes the viral regulatory pro- 
teins Tat and Rev (4, 5). Unlike Tat and Rev, which are es- 
sential for viral replication in culture (4), the Nef gene product 
is clearly dispensable, although investigators differ on whether 
Nef has a slight inhibitory effect (6-8), no detectable pheno- 
type (3, 9, 10), or a slight positive effect (11, 12) on the rate 
of replication. The difficulty of establishing a clear pheno- 
type for HIV-1 Nef in culture, and of identifying fully active 
copies of nef, has been compounded by the high variability 
of the Nef open reading frame between different viral iso- 
lates (13,  14). 
Recently, Kestler et al. (15) demonstrated that Nef is es- 
sential for both viral replication and pathogenesis in rhesus 
macaques infected with the mac239 proviral clone of simian 
immunodeficiency virus (SIV), 1 an animal model for HIV-1 
infection that accurately reproduces much of the pathology 
seen in humans. This study both emphasized the critical im- 
portance of this protein in the viral life cycle and also identified, 
for the first time, a cloned nefgene that clearly retained full 
1  Abbreviations used in this paper: cat, chloroamphenicol acetyl transferase; 
CMV-IE, cytomegalovirus immediate early; SIV, simian immunodeficiency 
virus. 
biological activity. Here, we demonstrate that stable expres- 
sion of this SIV Nef protein in human CD4 + T cells results 
in the downregulation of cell-surface CD4 expression and 
renders these cells resistant to infection by HIV-1. 
Materials  and Methods 
Construction and Use of Retroviral Vectors.  The nefgene was iso- 
lated from the SIVm~239  proviral done (15) by the PCR (16) using 
primers that introduced unique EcoRI (5') and Xhol (3') restric- 
tion enzyme sites. The nef gene was then inserted into the poly- 
linker present in the LXSN retroviral expression vector (17) where 
it would be transcribed under the control of the viral LTR pro- 
moter. Similar constructs containing the prokaryotic chloramphen- 
icol acetyl transferase (cat) gene (18) or the mutant M10 form of 
the HIV-1 rev gene (19) were also prepared. The resultant plasmids 
were transfected into the packaging cell line GP+ ENV-AM12 (20), 
and the released amphotropic retroviral particles used to infect the 
human CD4 + T ceil line CEM-SS (21). Infected CEM-SS cells 
were selected on the basis of acquisition of resistance to G418 and 
maintained  as a pool (CEM-NEFP) or subjected  to single-ceil  doning 
by end-point dilution  (all other cell lines). 
Immunological Reagents.  mAbs used in the flow cytometric anal- 
yses were obtained from Becton Dickinson & Co. (Mountain View, 
CA  [Leu3A]), Ortho  Pharmaceuticals,  Raritan,  NJ  (OKT4, 
OKT4B, OKT4C, OKT4D), and Olympus Immunochemical  (Lake 
Success, NY) (anti-HLA-ABC).  Quantitative fluorescence  standards 
(Quantum 27) were obtained from Flow Cytometry  Standards Corp. 
(Research Triangle Park, NC). The rabbit polyclonal antiserum 
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anti-Nef  antiserum (15) was a gift of K. Desrosiers (New England 
Regional Primate Center, Harvard Medical  School, Southborough, 
MA). 
Analysis of  Protein Expression.  Expression  of the 34-kD SIV Nef 
protein was confirmed  by incubation of 106 cells derived  from each 
CEM-SS subclone with [3SS]methionine  for 2 h as previously de- 
scribed (23). After cell lysis, radiolabeled  proteins were subjected 
to immunoprecipitation (23) using an antiserum obtained from an 
SIV-infected  rhesus  macaque  (15). Precipitated  proteins were resolved 
by electrophoresis through a 10% SDS-acrylamide  gel and visual- 
ized by autoradiography. 
The level of  expression of CD4 in the various transduced CEM- 
SS T cell lines was quantitated by Western blot analysis.  Cells (107) 
derived from the CEM-SS subclones and from the cell lines HeLa 
and HeLa/CD4 clone 1022 (24) were lysed in 1 ml of TNE (50 
mM  Tris-HC1, pH  8.0,  1%  NP-40,  2  mM  EDTA, 100  #M 
Na3VO4, 20 tzg/ml leupeptin) and immunoprecipitated overnight 
(23) at 4~  with 200 #1 of OKT4 prebound to  10%  protein 
A-Sepharose (Pharmacia  Inc., Piscataway,  NJ). The beads were ex- 
tensively  washed  before  adherent  proteins  were solubilized  by heating 
at 100~  in Laemmli  sample  buffer.  Precipitated  proteins were sepa- 
rated by electrophoresis through an 8% SDS-polyacrylamide  gel 
before transfer to nitrocellulose (Scheicher & Schuell, Inc., Keene, 
NH). The membrane was preincubated in 10 mM Tris-HC1, pH 
8.0, 150 mM NaC1, 0.5% Tween 20, 5% nonfat milk, and then 
hybridized overnight at room temperature using a 1:1000 dilution 
of  a rabbit anti-CD4 polyclonal  antibody (22). Anti-CD4 antibody 
binding was visualized  using a goat anti-rabbit antiserum  conjugated 
to alkaline phosphatase (GIBCO-BRL, Gaithersburg, MD). The 
quantitative recovery  of the ,,o55-kD CD4 protein was confirmed 
by the demonstration that immunoprecipitation of the superna- 
tant for a second time brought down minor and equal amounts 
of CD4 for all the CEM-SS cell lines tested. 
Cell Culture and Viral  Infection.  All CEM-SS ceil  lines  were main- 
tained in RPMI-1640 medium supplemented with 10% FCS and 
gentamycin. Transduced  cells were selected  and maintained in 0.8 
mg/ml G418. Viral replication was analyzed by infecting cells 
(5  x 10  s)  derived from each of the various CEM-SS subdones 
with 0.5 ml of a viral stock of the HIV-1 isolate  IIIB (19). Titration 
by end-point  dilution  demonstrated  that  this  stock contained 
~4  x 103 median tissue culture infectious doses per ml for CEM- 
SS cells. At 3 d after infection, the cells  were pelleted, washed, and 
resuspended at 106 cells per ml in fresh medium. This process was 
repeated at 2-d intervals  in conjunction with sampling  of the media 
for analysis  of viral replication rate. The level of p24 Gag secreted 
into the supernatant media over each 48-h period was determined 
using a quantitative ELISA  (DuPont Biotechnology,  Wilmington, 
DE). 
Transfection Assays.  Cells  (2  x  106) derived from the CEM-SS 
subclones were transfected (19) using plasmids (4 #g) containing 
the  cat  gene under  the  control  of the HIV-1 LTK promoter 
(BC12/HIV/CAT) or the cytomegalovirus  immediate early (CMV- 
IE) promoter (BC12/CMV/CAT) (25). The HIV/CAT phsmid was 
cotransfected with 2 #g of a plasmid (pcTat) encoding the HIV-1 
Tat trans-activator while the CMV/CAT plasmid was cotransfected 
with an equal level of a negative control plasmid (pBC12/CMV) 
(25). At 48 h after transfection, the cultures were harvested, and 
relative  levels  of  CAT enzyme activity, in counts per minute, deter- 
mined by the diffusion method (18). The presented values were 
adjusted for minor variability in the level of total protein in each 
extract, as determined by the method of Bradford (26). 
Figure 1.  Expression  of SIV Nef in human T cells. Expression  of the 
Nef protein of SIVmar  was examined  by immunoprecipitation  analysis 
(23) of radiolabeled cultures of the indicated  CEM-SS-derived cell cul- 
tures using an antiserum  obtained  from an SIV-infected  rhesus macaque 
(15). A specific  protein band that migrated  with the mobility  predicted 
for SIV Nef (•37  kD) was detected  in he, transduced cells exclusively. 
(Left) Relative migration of protein molecular  weight markers. 
Results 
To  examine  the  properties  of  the  SlVmar  nef gene 
product in culture, we stably transduced the HIV-1 permis- 
sive human  CD4 +  T  cell  line  CEM-SS  (21) with  am- 
photropic retroviral vectors designed to express either Nef, 
the prokaryotic cat gene or the trans-dominant  negative M10 
mutant of HIV-1  Key. (19) (Fig.  1). Transduced cells were 
maintained either as heterogeneous pools (CEM-NEFP) or 
as homogeneous subdones (CEM-NEF1, 4, 6, and 8; CEM- 
M10;  CEM-CAT and -CAT2).  Immunoprecipitation anal- 
ysis using antiserum derived from an SIV-infected macaque 
(15) confirmed expression  of the ,v34-kD SIV Nef protein 
in CEM-SS cells transduced with the retroviral Nef expres- 
sion construct (Fig.  1,  lanes  4-8). 
Although it has been argued that expression of HIV-1 nef 
results in a significant downregulation of cell-surface CD4 
expression  (27),  others have been unable to reproduce this 
effect (7, 8,  10). We examined the effect of SIV Nef on the 
cell-surface expression of CD4 and other antigens using flow 
cytometric analysis (Fig. 2 A). Expression of cell-surface CD4 
was uniformly high (>~94% positive)  on the Nef-  T  cells 
(Fig. 2 B). In contrast, Nef-expressing T cells displayed low 
levels of CD4 positivity ranging from a high of *28%  in 
the undoned CEM-NEFP cells to a low of'~3% in the CEM- 
NEF1  subclone.  This reduction proved stable  over several 
months in culture and was not due to a conformational  change 
in the CD4 epitope or masking, as essentially identical data 
were  obtained with  a range of anti-CD4  mAbs  (Leu3A, 
OKT4, OKT4B, OKT4C, and OKT4D) specific for different 
CD4 epitopes,  as well as with a rabbit polyclonal anti-CD4 
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Figure 2.  Expression ofSIV nefinhibits  cell-surface  expression of CD4. 
The various CEM-SS subclones were analyzed by flow cytometry using 
mAbs specific for CD4, HLA-ABC, and other lymphocyte cell-surface 
markers. (,4) Representative fluorescence intensity  profiles obtained using 
K-PE-conjugated LEU3A anti-CD4 mAb are shown for the CEM-SS sub- 
clones CEM-NEF1 and CEM-CAT. In this experiment, the mean fluores- 
cence intensity  was 0.846 for the CEM-NEF1 subclone, and 18.55 for the 
CEM-CAT subclone whereas the background fluorescence level, obtained 
using an K-PE conjugated negative control mAb, was 0.261. By compar- 
ison to quantitative fluorescence standards, these data indicate a drop from 
a mean of '~4.8  x  10  s cell-surface CD4 receptors per CEM-CAT cell to 
"~1.5  x  10  ~ CD4 receptors per CEM-NEF1  cell. (B) This graph com- 
pares the percentage of cells in each subclone positive for cell-surface CD4 
expression (solid bars) or HLA-ABC expression (hatched  bars). Positivity 
is here arbitrarily defined as a fluorescence intensity  greater than 1.96 on 
the scale given in A. 
antiserum  (22).  This  effect  was  also  specific, in  that  no 
significant reduction in the cell-surface expression of HLA- 
ABC,  HLA-DR,  TCR,  intercellular  adhesion molecule 1 
(ICAM-1), CD38, CD45, or CD69 was observed (Fig. 2 B 
and data not shown). Quantitative flow cytometric analysis 
of the CEM-SS subdones CEM-NEF1 and CEM-CAT con- 
firmed a 97% reduction in the average number of cell-surface 
CD4 molecules on the surface of these Nef-expressing T cells 
(Fig. 2 A). Of interest, the two subclones that displayed the 
Figure 3.  Expression of SIV Nef does not affect the steady-state level 
of CD4 protein  expression. Western blot analysis was used to compare 
the relative level of the •55-kD  CD4 protein expression in the indicated 
CEM-SS subclones and in the cell lines HeLa  (negative control) and 
HeLa/CD4 clone 1022 (24) (positive control).  (Left) R~lative migration 
of protein  molecular weight markers. 
greatest reduction in cell-surface CD4 expression, i.e., CEM- 
NEF1 and CEM-NEF8, also expressed the highest level of 
Nef (Fig.  1, lanes 5 and 8). 
To identify the level at which Nef affected cell-surface ex- 
pression of CD4, we next measured the steady-state level of 
CD4 protein expression using Western blot analysis (Fig. 3). 
These data revealed that the level of expression  of CD4 in 
the Nef  + T  cells was unchanged relative  to that observed 
in the Nef-  cells. Immunoprecipitation analysis of pulse- 
labeled cells demonstrated that the rate of CD4 protein syn- 
thesis was also unaffected by coexpression of Nef (data not 
shown). We therefore conclude that dowuregnlation of cell- 
surface CD4 expression by Nef results from the sequestra- 
tion of CD4 in a currently unidentified intracellular com- 
partment. However, the observation that the relative mobility 
of the CD4 glycoprotein in the CEM-Nef cells was indistin- 
guishable from that observed in the parental CEM-SS cells 
suggests that Nef does not affect the normal posttranslation 
processing of CD4. 
The CD4 molecule is the cell-surface receptor for both 
HIV-1 and SIV (4). Inhibition of cell-surface CD4 expres- 
sion might therefore be predicted to reduce the efficiency of 
viral infection of T  cells in culture. To test this possibility, 
we infected CEM-SS cells, three transduced Nef-  cell lines 
(CEM-CAT,  -CAT2,  and -M10)  and five Nef  +  cell  lines 
(NEFP,  1, 4, 6,  and 8) with a constant level of the HIV-1 
isolate IIIB. The rate of spread of the virus was then moni- 
tored by measurement of supernatant p24 Gag protein. As 
shown in Fig. 4, both the parental CEM-SS T cells and the 
two subclones transduced with the cat gene were highly per- 
missive for HIV-1 replication. The cell line CEM-M10 ex- 
presses the tram-dominant  negative M10 mutant of HIV-1 
Rev previously shown to confer significant resistance to HIV-1 
replication in culture (19). The data presented in Fig. 4 confirm 
this earlier finding by demonstrating a >--100-fold  inhibition 
in the rate of viral replication in the CEM-M10 cells when 
compared with the positive controls. Remarkably, analysis 
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Figure 4.  Expression of SIV Nef in human T cells inhibits infection 
by HIV-1. Cultures of the indicated CEM-SS-derived subclones were in- 
fected (19) with equal amounts of a titered HIV-1 virus stock and the rate 
of viral replication monitored at 2-d intervals by quantitation of the level 
of released p24  Gm protein. 
(HIWCAT) or under the control of a human cytomegalo- 
virus promoter (CMWCAT) (25).  In the former case, we 
also cotransfected an expression vector encoding the HIV-1 
Tat  trans-activator  (25).  If Nef were a specific inhibitor of 
LTR-specific gene expression, we would predict that the level 
of CAT expression induced by the HIWCAT vector would 
be markedly reduced in cells that express Nef, when com- 
pared to the level seen with the CMWCAT plasmid. How- 
ever, these studies failed to demonstrate any inhibitory effect 
of SIV Nef on HIV-l-specific gene expression (Table 1). These 
observations are therefore consistent with earlier reports that 
have failed to detect an inhibitory effect of either SIV Nef 
or HIV-1 Nefon viral gene expression in culture (3, 9, 10, 15). 
Discussion 
The nefgene of the mac239 proviral done of SIV is unique 
in that the full biological activity of the encoded protein has 
been validated in vivo (15). In this report, we have used human 
CD4 + T  cells transduced with a retroviral  nef expression 
vector to examine the in vitro properties of this viral gene 
product. We demonstrate that expression  of SIV Nef dra- 
matically and specifically reduces call-surface expression  of 
the CD4 glycoprotein receptor but has no detectable effect 
on the steady-state level of CD4 protein expression.  These 
observations therefore serve to validate the similar, yet con- 
troversial (7, 8, 10), data of Garcia and Miller (27) obtained 
using the nef gene of HIV-1 strain SF2. Most importantly, 
of the four Nef-expressing CEM-SS subdones demonstrated 
an even more dramatic inhibition in the rate of viral replica- 
tion, although a low level of virion production did remain 
detectable throughout the experimental time course. The pool 
of G418-resistant T cells (CEM-NEFP) obtained after the initial 
infection of CEM-SS cells with the retroviral Nef expression 
vector proved somewhat more permissive for the spread of 
HIV-1 (Fig. 4). We hypothesize that this intermediate pheno- 
type reflects the heterogeneous nature, in terms of proviral 
integration site and Nef expression, of this transduced T cell 
population when compared with the Nef-expressing subclones, 
a hypothesis also consistent with the broad range of cell-surface 
CD4 expression observed on these cells by flow cytometry 
(data  not shown). 
The data presented in Fig. 4 demonstrate that expression 
of Nef can render T  cells resistant  to HIV-1 infection. As 
Nef expression  inhibits cell-surface expression  of CD4,  it 
seemed likely that this resistance  resulted from a block to 
viral penetration. Previous  studies demonstrating that cul- 
tures displaying low levels of cell-surface CD4 are less sus- 
ceptible to infection by HIV-1  are consistent with this in- 
terpretation (28).  However, it has also been proposed that 
Nef might inhibit transcription directed by the HIV-1 LTR 
(29, 30). To test whether the inhibition of HIV-1 replication 
in these Nef-expressing CEM-SS cells resulted from an inhi- 
bition of HIV-1 LTR-specific gene expression, we transfected 
Nef-expressing and control T cells with plasmids containing 
the cat indicator gene under the control of the HIV-1 LTR 
Table  1.  SIV Nef Does Not Inhibit HIV-I  LTR-driven 
Gene Expression 
CAT activity 
HIV/CAT  Ratio 
Cell line  plus Tat  CMV/CAT  (HIV/CMV) 
A 
CEM-SS  11,463  9,534  1.20 
CEM-M10  10,633  13,380  0.79 
CEM-NEFP  6,228  12,470  0.50 
CEM-NEF1  32,498  27,647  1.18 
CEM-NEF4  26,019  15,300  1.70 
CEM-NEF6  13,124  14,905  0.88 
CEM-NEF8  15,857  16,477  0.96 
The effect of Nef on HIV-1 LTR-specific gene expression was examined 
by transfection  (19) of the indicated CEM-SS subclones with plasmids 
containing the indicator gene cat under the control of either the HIV-1 
LTR or the CMV-IE promoter (25). In the former case, a plasmid that 
directs expression of the HIV-1 Tat trans-activator was also cotransfect- 
ed. A comparison of the level of CAT enzyme activity (18) induced by 
the HIV-1 LTR construct with that induced by the CMV promoter con- 
struct demonstrates that these promoters  give comparable levels of en- 
zyme activity in transfected cells regardless of Nef expression. These data 
are representative of three independent experiments and have been cor- 
rected for the low level of background activity (364 cpm) observed in 
mock-transfected  CEM-SS cells. 
1564  Downregulation of the CD4 Receptor by NEF T  cells expressing Nef are shown to be highly resistant  to 
HIV-1 infection, yet retain the ability to support effident tran- 
scription  from  the  HIV-1  LTR  promoter.  We  therefore 
hypothesize that the downregulation of cell-surface  CD4 has 
rendered these cells, in effect, resistant to superinfection by 
SIV or HIV-1. 
If downregulation of surface CD4, and the associated in- 
hibition  of superinfection,  represents  the only function  of 
Nef, then why does this enhance virus spread in vivo? It does 
not appear probable that inhibition of superinfection by ex- 
ogenous virions is likely to provide a major selective advan- 
tage, as the virus load in vivo is low compared with the number 
of available CD4 + target cells (15). We hypothesize, instead, 
that  downregulation  of CD4  is  designed  to  facilitate  the 
efficient release of infectious progeny virions from the infected 
cell by preventing the sequestration of viral envelope (Env) 
protein  or  by  preventing  continuous  CD4-mediated  re- 
infection. 
Several groups have demonstrated  that  CD4  and HIV-1 
Env can functionally interact in the endoplasmic reticulum 
(EK) (31-33). This process can lead to the retention of both 
proteins within the ER and hence to their functional inacti- 
vation (31-33). Extensive superinfection of cultured human 
T  cells by HIV-1 has  also been reported (34, 35). Whereas 
such  superinfection  results  in  the  accumulation  of large 
amounts ofproviral DNA, it does not augment virus produc- 
tion and, therefore, presumably inhibits virus spread (34, 35). 
Particularly relevant is the recent demonstration by Marshall 
et al. (36) that high level expression of cell-surface CD4 can 
effectively block the cell-to-cell transmission of HIV-1 in cul- 
ture, but does not inhibit  infection by exogenously added 
virus. These authors suggest that this inhibition of virus spread 
results from the inability of progeny virions to effectively dis- 
engage from infected cells  that  express high  levels of cell- 
surface CD4. Conditions that reduce the ability of released 
virions to diffuse away from an infected T cell that continues 
to express surface CD4 would therefore be predicted to max- 
imize the positive effect of Nef on the rate of spread of HIV-1. 
We hypothesize that such conditions might well include the 
far greater cell density that exists,  for example, in an HIV- 
1-infected lymph node in vivo when compared with an in 
vitro T cell culture. Precedent for a viral protein that func- 
tions to enhance viral release and spread by removal of receptors 
from the surface of infected cells exists in the form of influenza 
virus neuraminidase, which has been shown to destroy such 
receptors by removal of terminal sialic acid residues (37). These 
considerations suggest that demonstration of a positive effect 
of Nef on HIV-1 replication  in vitro should be achievable 
by appropriate modification of cell culture conditions, as has 
already been demonstrated  by some groups  (11, 12). 
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